Impact of short-form, case-based continuing medical education on community clinicians' knowledge and competence in optimizing bispecific antibody therapy for Relapsed/Refractory multiple myeloma

Abstract

Abstract Background: Despite progress in the management of multiple myeloma (MM), the disease remains largely incurable. Patients eventually develop resistance to therapies and relapse, leading to the development of relapsed/refractory (RRMM). Thus, more efficacious, novel therapies that can evade resistance to prior treatment have recently emerged. Several bispecific T-cell antibodies targeting CD3 and a second cell surface target, such as B cell maturation antigen (BCMA) or G protein–coupled receptor, family C, group 5, member D (GPRC5D), have been approved for patients with heavily pre-treated RRMM. Due to the expansion of the treatment landscape of RRMM, clinicians need education on the clinical profiles of novel bispecific antibodies, including considerations for their use in the community care setting, in order to optimize patient outcomes. Purpose: This study evaluated whether digital, short-form, case-based education improves clinicians' knowledge and competence in optimizing bispecific antibody regimens for RRMM. Methods: US-based hematologists and hematologist-oncologists from community (57%) and academic (43%) settings participated in an accredited continuing medical education (CME) activity entitled “Optimizing Outcomes in Relapsed/Refractory Multiple Myeloma With Bispecific Antibodies: A Community Clinician's Roadmap.” This enduring activity featured expert dialogue. Pre- and post-assessments measured knowledge, competence, and educational impact. Data were analyzed overall and by specialty. Results: By August 4, 2025, 2,164 clinicians completed the activity. Knowledge and competence improved significantly among hematologist-oncologists (32%) and hematologists (50%). Notable gains included understanding bispecific antibodies' role in community care (55%), clinical benefits for heavily pretreated RRMM patients (56%), and adverse event management (30%). Post-activity, learners felt more confident integrating bispecific antibodies and expressed interest in further education about emerging data on combination regimens containing bispecific antibodies (80%) and how to effectively integrate them into community care (70%). Conclusions: Digital, short-form, case-based CME effectively enhanced clinician knowledge and competence in bispecific antibody use for RRMM and identified ongoing educational needs to inform future CME on this topic.